- Home
- TVGN vs TCRX Comparison
TVGN vs TCRX Comparison
Compare TVGN & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TVGN | TCRX |
|---|---|---|
| Founded | 2020 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.9M | 75.1M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | TVGN | TCRX |
|---|---|---|
| Price | $9.19 | $1.11 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 22.7K | ★ 937.1K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 12.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,325,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $19.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 266.65 |
| 52 Week Low | $0.14 | $0.88 |
| 52 Week High | $10.76 | $2.57 |
Technical Indicators
Market Signals| Indicator | TVGN | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 66.71 | 44.12 |
| Support Level | $0.47 | $0.93 |
| Resistance Level | $9.40 | $1.21 |
| Average True Range (ATR) | 0.90 | 0.10 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 85.30 | 5.27 |
Price Performance
Historical ComparisonAbout TVGN Tevogen Bio Holdings Inc.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.